Biogen Inc.
BIIB Healthcare Drug Manufacturers General
Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024. In the quarter to June 2026, revenue grew 3.42%, EPS fell 84.8%, free cash flow grew 103.3% and total debt rose 16.0%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.
Follow BIIB
Biogen Inc. (BIIB) Return on invested capital
Biogen Inc.'s return on invested capital over the twelve months to 30 June 2026 was 3.11%, down 2.5 percentage points from fiscal 2025 (5.61%). Over the past ten years it has ranged from 4.91% (fiscal 2023) to 33.0% (fiscal 2019); the current reading is higher than 18% of that period. That is below the Drug Manufacturers General industry median of 6.11% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 5.61% | (1.83) |
| FY2024 | 7.44% | 2.53 |
| FY2023 | 4.91% | (9.82) |
| FY2022 | 14.7% | 1.51 |
| FY2021 | 13.2% | (7.13) |
| FY2020 | 20.4% | (12.69) |
| FY2019 | 33.0% | 9.19 |
| FY2018 | 23.9% | 1.34 |
| FY2017 | 22.5% | (0.91) |
| FY2016 | 23.4% | (1.10) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| NVO Novo Nordisk A/S compare | 28.7% |
| BMY Bristol Myers Squibb Company compare | 13.7% |
| AMGN Amgen Inc. compare | 13.0% |
| GSK GSK PLC Sponsored ADR compare | 12.6% |
| AZN AstraZeneca PLC compare | 11.7% |
| SNY Sanofi compare | 6.58% |
| PFE Pfizer Inc. compare | 6.30% |
| BIIB Biogen Inc. | 3.11% |
| GILD Gilead Sciences, Inc. compare | −4.48% |
| Drug Manufacturers General industry median | 6.11% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on BIIB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement